BioCentury
ARTICLE | Clinical News

argenx's CD70 mAb leads to 92% response rate in AML

November 1, 2018 7:01 PM UTC

In an abstract released ahead of next month’s American Society of Hematology meeting, argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) said cusatuzumab (ARGX-110) plus Vidaza azacitidine led to an overall response rate (ORR) of 92% in the Phase I portion of a Phase I/II trial to treat newly diagnosed acute myelogenous leukemia. The biotech gained $16.04 (20%) to $96.05 on NASDAQ on Thursday; it added €9.60 (14%) to €79.70 on Euronext.

Among 12 evaluable AML patients unfit for intensive chemotherapy, the human IgG1 mAb against CD70 plus Vidaza led to nine complete responses with or without hematologic recovery, one case of morphologic leukemia-free status and one partial response at the July 16 cut-off. Five patients were negative for minimal residual disease (MRD), and the median duration of response was 6.9 months. argenx said cusatuzumab was well tolerated...

BCIQ Target Profiles

CD70 (CD27L)